TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04662632
Drug: Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Forty-two days (minimum) systemic antibiotic administration adjuvant to two-stage exchange arthroplasty with temporary antibiotic-impregnated cement spacer per standard of care. Antibiotics will be selected by treatment provider and administered in accordance with national and local treatment guidelines.
Study: NCT04721691
Drug: Epidiolex 100 mg/mL Oral Solution
Normalized name: Epidiolex 100 MG/ML Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidiolex is a schedule 5 controlled substance that is a colorless to yellow oral liquid solution that is prepackaged into 100mL vials with 5mL syringes for use. It is typically used for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet Syndrome in patients 2 years of age and older.
Study: NCT04865458
Drug: HEC89736
Approvals — FDA: no, EMA: no, PMDA: no
Description: HEC89736 tablets QD every 28 days for each cycle
Study: NCT05775575
Drug: TQB3909 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB3909 is an inhibitor targeting BCL-2 protein
Study: NCT03547232
Drug: Indomethacin SR
Normalized name: Indomethacin SR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin SR 50mg given q12h from admission day 1 to day 7
Study: NCT03547232
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Similar shape and size suppositories (Placebos) without indomethacin given q12h from admission day 1 to day 7
Study: NCT06131593
Drug: TAPB with methylprednisolone as an adjuvant to local anesthetics
Normalized name: Aldex AN
DrugBank: Doxylamine (DB00366)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients will receive TAPB with methylprednisolone as an adjuvant to bupivacaine and lidocaine local anesthetics
Study: NCT06453876
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active comparator
Study: NCT05784597
Drug: [68Ga]Ga-OncoFAP administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will receive a single intravenous bolus administration of 250 MBq (225 - 275 MBq)
Study: NCT04595370
Drug: AZD9977
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive AZD9977 as per the arms they are randomized.
Study: NCT03399773
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT05034887
Drug: T-DXd, Durvalumab and Capecitabine Combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administer each cycle over 21 days. T-DXd is administered by intravenous infusion at 5.4 mg/kg every 21 days (every 3 weeks). Capecitabine is given at 750 mg/m2 BID, taken orally for 14 days, followed by a drug holiday from the evening of Day 15 to the morning of Day 22 (Day 1 of the next cycle). Durvalumab is administered at 1500 mg by intravenous infusion over 60 minutes every 21 days (every 3 weeks). As neoadjuvant chemotherapy, administer T-DXd, Capecitabine, and Durvalumab in combination on a q3w schedule for 3 cycles. As adjuvant chemotherapy consists of T-DXd, Capecitabine, and Durvalumab in combination on a q3w schedule for 3 cycles, followed by Durvalumab monotherapy on a q4w schedule until 10 cycles are completed.
Study: NCT05014542
Drug: Conventional Medical Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants could take their standard conventional medical treatment or analgesics. Analgesics therapy is prescribed by their general practitioner. The dose of analgesics could be modified according to participants' symptoms intensity.
Study: NCT06157827
Drug: LBL-024 for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial dose-MTD; Q3W; intravenous infusion
Study: NCT06563349
Drug: Intravenous magnesium sulfate
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative intravenous magnesium sulfate infusion.
Study: NCT06462573
Drug: general anaethesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: which patients will undergo ESWL under systemic analgesia. The latter will be achieved using one gram of paracetamol IV infusion at the beginning of the procedure.~In case of unsatisfactory pain control in either group, systemic analgesia using IV Ketorolac injection will be used on demand or the required dose will be recorded at the end of the session.
Study: NCT04933227
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 1000 mg/m\^2/d will be administered orally (PO) twice daily (bid) on Days 1-14 during Cycles 1-4.
Study: NCT05852717
Drug: GDP
Normalized name: GDPase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine Cisplatin Dexamethasone
Study: NCT06034275
Drug: VIP943 (QW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VIP943 will be administered by IV Infusion weekly
Study: NCT06034275
Drug: VIP943 (BIW)
Normalized name: BREATHING CIRCUIT,BIWAZE COUGH,W/MOUTHPIECE,STANDARD
Approvals — FDA: no, EMA: no, PMDA: no
Description: VIP943 will be administered by IV Infusion bi-weekly
Study: NCT05612607
Drug: Immunoglobulin replacement therapy (IGRT)
Normalized name: immunoglobulin A
Approvals — FDA: no, EMA: no, PMDA: no
Description: IGRT discontinuation will be dependent on participant's SMB levels. If SMB cells are ≥ 2%, IGRT will be discontinued. If SMB cells are \< 2%, the patient will remain on IGRT and a maximum of 40 mL of blood will be drawn again in 3-6 months to reassess SMB levels and eligibility for IGRT discontinuation.
Study: NCT05496738
Drug: PF-07264660 intravenous single ascending dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-07264660 will be administered intravenously in single ascending doses
Study: NCT05496738
Drug: PF-07264660 subcutaneous multiple ascending dose
Normalized name: Influenza, high-dose, quadrivalent, PF
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-07264660 will be administered subcutaneously in multiple ascending doses
Study: NCT05975125
Drug: Vitamin C 500 MG Oral Tablet
Normalized name: vitamin C 500 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: compare between Vitamin C with iron supplement and iron supplement alone in prevention of anemia in pregnancy.
Study: NCT06604598
Drug: IBU-PCT-DEX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (Peinlos) 2x400 mg iv, Paracetamol (Bernofarm) 2x1 gr iv, dexamethasone (Phapros) 2x5 mg iv will be given with interval 8 hour, within the IBU-PCT-DEX intervention.
Study: NCT06604598
Drug: IBU-PCT-placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (Peinlos) 2x400 mg iv, Paracetamol (Bernofarm) 2x1 gr iv, and 2xplacebo (normal saline alike dexamethasone) will be given with interval 8 hour, within the IBU-PCT-placebo intervention
Study: NCT06604598
Drug: PCT-placebo-placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol (Bernofarm) 2x1 gr iv, 2xplacebo (normal saline alike paracetamol), 2xplacebo (normal saline alike dexamethasone) will be given with interval 8 hour, within the PCT-placebo-placebo intervention.
Study: NCT06253429
Drug: Thioctic Acid 333 MG Oral Capsule
Normalized name: thioctic acid 333 MG Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant compound which serve as a cofactor for mitochondrial respiratory enzymes
Study: NCT04802785
Drug: Dextrose Oral Tablet, Chewable
Normalized name: Dextrose Oral Tablet, Chewable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextrose 13.5 g per os
Study: NCT04802785
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid 150 mg per os
Study: NCT04802785
Drug: Probiotic Formula
Normalized name: Probiotic Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule per os.
Study: NCT04802785
Drug: Melatonin 5 mg
Normalized name: melatonin 5 MG
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Melatonin 5 mg per os.
Study: NCT00002226
Drug: SU5416
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04784780
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with chronic constipation are administered placebo for 12 weeks
Study: NCT05667402
Drug: TBF regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subjects receive TBF conditioning regimen (Thiotepa, Busulfan, Fludarabine) before allo-HSCT.
Study: NCT05667402
Drug: modified BuCY2 regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subjects receive modified BuCY2 conditioning regimen (Busulfan, Cytarabine, ATG, Cyclophosphamide, CCNU) before allo-HSCT.
Study: NCT05001555
Drug: Dexketoprofen/Vitamin B
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule containing 25 mg of dexketoprofen / vitamin B (thiamine mononitrate 100 mg, Pyridoxine hydrochloride 50 mg, Cyanocobalamin 0.50 mg), orally, every 8 hours, for 7 days.
Study: NCT05156125
Drug: VTX002
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose A tablet administered orally once daily
Study: NCT05156125
Drug: VTX002
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose B Tablet administered orally once daily
Study: NCT05156125
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Tablet for VTX002 administered orally once daily
Study: NCT05848375
Drug: naropeine or chirocaine (Arthroscopic rotator cuff repair under LRA associated to GA)
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loco Regional Anesthesia is performed by injecting anesthetic (between 10 and 20 ml of naropeine or chirocaine) into the interscalene nerve block under ultrasound guidance associated to General Anesthesia performed by injection of diprivan and ultiva.
Study: NCT05848375
Drug: naropeine or chirocaine (Arthroscopic rotator cuff repair under LRA)
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loco Regional Anesthesia is performed by injecting anesthetic (between 10 and 20 ml of naropeine or chirocaine) into the interscalene nerve block under ultrasound guidance
Study: NCT06433011
Drug: r-tPA
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulse spray and infusion
Study: NCT06362642
Drug: PC14586
Approvals — FDA: no, EMA: no, PMDA: no
Description: First-in-class, oral, small molecule p53 reactivator that is selective for the TP53 Y220C mutation.
Study: NCT04877691
Drug: Medi-546
Normalized name: Medi-Lyte
DrugBank: MEDI-547 (DB18360)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will have IP administered or will self-administer IP under supervision by site staff at Week 0 and Week 1 and, for patients participating in the OLE period, at Week 52. For weekly doses coinciding with subsequent on-site visits, patients will also have IP administered or will self-administer IP under supervision by site staff, and in addition will receive a set of kits (including back-up kits) for at-home administration.
Study: NCT04877691
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for injection in aPFS
Study: NCT05198362
Drug: Tesomet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination
Study: NCT04920292
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo tablet is made using the same non-active ingredients and matches the investigational tablet.
Study: NCT05663593
Drug: HSK31858, tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting dose in single ascending dose: 5 mg
Study: NCT05663593
Drug: Placebo, tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT04903509
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04903509
Drug: Saxenda®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saxenda®
Study: NCT04903509
Drug: Paracetamol-ratiopharm®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol-ratiopharm®
Study: NCT05919823
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Capsules
Study: NCT05726383
Drug: Iscador*P
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iscador P given for 2 cycles with follow up imaging done every 2 cycles. If imaging is negative patient remains on study for 13 cycles. If new lesion is found, then patient is off study.
Study: NCT05792254
Drug: Huaier granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Huai Er granules, 20 g once, 3 times a day, continued to progress or intolerance toxicity.
Study: NCT05785767
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Q3W as IV co-infusion
Study: NCT06618534
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A standard dose of azithromycin (500 mg) will be delivered by oral route.
Study: NCT04938466
Drug: Long-Acting Growth Hormone (LAGH)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting growth hormone (LAGH) treatment
Study: NCT05735496
Drug: TQB2102 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB2102 is an antibody-drug conjugate comprised of a humanised antibody against HER2, a enzyme-cleavable linker, and a topoisomerase I inhibitor payload.
Study: NCT05379985
Drug: RMC-6236
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Tablets
Study: NCT06023368
Drug: Num Vapocoolant Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spray applied around port prior to access
Study: NCT06160440
Drug: SC1011
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject in the SAD groups participated in 1 treatment period only and reside at the clinical research unit (CRU) from Day -1 (the day before dosing) to Day 7 (144 hours post dose).
Study: NCT05058638
Drug: Aquamin
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will take a 90-day supply of Aquamin®, 4 capsules per day; 2 to be taken in the morning and 2 in the evening (containing approximately 800 mg calcium/day).
Study: NCT05574400
Drug: Caffeine citrate
Normalized name: Caffeine Citrate
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-dose caffeine citrate (1.5 mg/kg)
Study: NCT05574400
Drug: Caffeine citrate
Normalized name: Caffeine Citrate
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose Caffeine citrate (3 mg/kg)
Study: NCT04546620
Drug: R-CHOP
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm A patients will receive R-CHOP alone.
Study: NCT06092983
Drug: HS-10383 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: HS-10383 Placebo administered as one 50 mg, 150 mg, 300 mg and 450 mg capsule once daily, depending upon randomization.
Study: NCT04814433
Drug: Lidocaine Hydrochloride with Epinephrine
Normalized name: epinephrine / lidocaine hydrochloride Injection [Xylocaine with Epinephrine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical lidocaine product is FDA approved as an amide local anesthetic in any indication for relief of pain associated with superficial minor surgery and as an adjunct for local infiltration anesthesia. It is frequently used as a standard local anesthetic for surgical procedures.~Each mL contains lidocaine hydrochloride and epinephrine, with 0.5 mg sodium metabisulfite as an antioxidant and 0.2 mg citric acid as a stabilizer.~Total of 5 mLs per open surgical study arm involving lidocaine hydrochloride and epinephrine will be given
Study: NCT05257018
Drug: R-CDOP+intrathecal MTX
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-CDOP+intrathecal MTX：~* Rituximab 375 mg / m\^2，D1~* Cyclophosphamide 750 mg / m\^2，D2~* Doxorubicin Hydrochloride Liposome Injection 35mg / m\^2，D2~* Vincristine 1.4mg/m\^2 (dose capped at 2 mg)，D2~* Prednisone 50 mg， bid D2-6~* Cycle1-5：Intrathecal MTX 12 mg + DXM 5 mg after chemotherapy （PK patients will be given 24 h after chemotherapy）
Study: NCT05726630
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05431179
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: After 16 weeks in the open-label Ibrutinib phase, participants will receive placebo administered by IV every 2 weeks for 3 administrations and then every 4 weeks thereafter.
Study: NCT05803551
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 0.9% saline infusions for three consecutive days.
Study: NCT05052307
Drug: Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine
Study: NCT05052307
Drug: ChAdOx1 nCoV-19 Covid-19 Vaccine
Normalized name: COVID-19 VACCINE ADENOVIRUS-26
Approvals — FDA: no, EMA: no, PMDA: no
Description: ChAdOx1 nCoV-19 Covid-19 Vaccine
Study: NCT05052307
Drug: Ad26.COV2.S COVID-19 Vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad26.COV2.S COVID-19 Vaccine
Study: NCT05105971
Drug: BAT6026
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase 1 dose titration study from BAT6026 0.01mg/kg to 10mg/kg, then choose a proper dose for amplification study based on DLT result
Study: NCT06300905
Drug: test product
Normalized name: Patch test product
Approvals — FDA: no, EMA: no, PMDA: no
Description: toothpaste containing 0.45% stannous fluoride
Study: NCT06300905
Drug: Control product
Normalized name: Patch test control product
Approvals — FDA: no, EMA: no, PMDA: no
Description: toothpaste containing 0.76% sodium monofluorophosphate
Study: NCT06429930
Drug: L608 Liposomal inhalation solution
Normalized name: amikacin liposomal Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be randomized at a ratio of 1:1 (for sentinel dosing) followed by 5:1 for the rest of the cohort to receive the assigned dose of L608 or placebo.
Study: NCT06429930
Drug: Placebo Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be randomized at a ratio of 1:1 (for sentinel dosing) followed by 5:1 for the rest of the cohort to receive the assigned dose of L608 or placebo.
Study: NCT05639712
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patient is given standardized questions about their well-being and affective state before and after the administration of placebo intravenously. This is carried out on the operating table right before anesthesia
Study: NCT05639712
Drug: Fentanyl 0.025 mg i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patient is given standardized questions about their well-being and affective state before and after the administration of fentanyl 0.025 mg intravenously . This is carried out on the operating table right before anesthesia
Study: NCT05639712
Drug: Fentanyl 0.05 mg i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patient is given standardized questions about their well-being and affective state before and after the administration of fentanyl 0.05 mg intravenously . This is carried out on the operating table right before anesthesia
Study: NCT05639712
Drug: Fentanyl 0.1 mg i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patient is given standardized questions about their well-being and affective state before and after the administration of fentanyl 0.1 mg intravenously . This is carried out on the operating table right before anesthesia
Study: NCT06140238
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline administration 15 minutes before start surgical operation
Study: NCT05415397
Drug: Celecoxib 400mg
Normalized name: CELECOXIB 400MG CAP
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib add-on (400mg daily) add-on to treatment as usual (standard antidepressant treatment)
Study: NCT05415397
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo add-on to treatment as usual (standard antidepressant treatment)
Study: NCT06509074
Drug: Beta blocker
Normalized name: Beta blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pragmatic design. Any beta-blocker with alpha or NO activity may be used
Study: NCT04917289
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Started chemotherapy or change the current adjuvant therapy
Study: NCT06499948
Drug: Treatment with Spironolactone followed by Dapagliflozin followed by their combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: After titrating the renin-angiotensin-system inhibitor dose, patients will receive 25 mg of Spironolactone once daily for 4 weeks. Spironolactone will be stopped after 4 weeks. The first treatment period will be followed by 4 weeks of wash-out. After the first wash-out period, treatment with Dapagliflozin will be started. Patients will receive 10 mg of Dapagliflozin once daily for 4 weeks. Dapagliflozin will be stopped after 4 weeks. The second treatment period will be followed by 4 weeks of wash-out. After the second wash-out period, treatment with both Spironolactone 25 mg and Dapagliflozin will be started. Patients will receive 25 mg of Spironolactone once daily in combination with 10 mg of Dapagliflozin daily for a duration of 4 weeks. Spironolactone and Dapagliflozin will be stopped after 4 weeks. The third treatment period will be followed by 4 weeks of wash-out, after which the study will be finalized.
Study: NCT06499948
Drug: Treatment with Dapagliflozin followed by Spironolactone followed by their combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: After titrating the renin-angiotensin-system inhibitor dose, patients will receive 10 mg of Dapagliflozin once daily for 4 weeks. Dapagliflozin will be stopped after 4 weeks. The first treatment period will be followed by 4 weeks of wash-out. After the first wash-out period, treatment with Spironolactone will be started. Patients will receive 25 mg of Spironolactone once daily for 4 weeks. Spironolactone will be stopped after 4 weeks. The second treatment period will be followed by 4 weeks of wash-out. After the second wash-out period, treatment with both Spironolactone and Dapagliflozin will be started. Patients will receive 25 mg of Spironolactone once daily in combination with 10 mg of Dapagliflozin daily for a duration of 4 weeks. Spironolactone and Dapagliflozin will be stopped after 4 weeks. The third treatment period will be followed by 4 weeks of wash-out, after which the study will be finalized.
Study: NCT06132360
Drug: RN0191
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a randomized, placebo-controlled, single ascending-dose (SAD) study of RN0191 administered SC to adult subjects with elevated LDL-C. Subjects who have signed an Ethics Committee (EC)-approved informed consent form (ICF) and have met all the protocol eligibility criteria during screening may be enrolled into the study.
Study: NCT04165486
Drug: ION464
Approvals — FDA: no, EMA: no, PMDA: no
Description: ION464 will be administered by IT injection.
Study: NCT04165486
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: ION464-matching placebo will be administered by IT injection.
Study: NCT05994534
Drug: Cysteamine Bitartrate
Normalized name: Cysteamine Bitartrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose, tablets at current therapeutic dose
Study: NCT06218784
Drug: Placebo Capsule (Part 1)
Normalized name: PLACEBO CAP/TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose: b.i.d for 7 days